NCT06824701

Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

A Phase 1b Study of Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphomas (TARZAN Trial)

• Status: Suspended
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: University of Utah · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical trial is to learn if the study drug Tazemetostat combined with Zanubrutinib and anti-CD20 monoclonal antibody is safe and effective in treating patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.

Conditions

• Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	Tazemetostat	Tazemetostat will be self-administered BID as an oral treatment on a 28-day cycle.
DRUG	Zanubrutinib	Zanubrutinib will be self-administered BID as an oral treatment on a 28-day cycle.
DRUG	Rituximab	Rituximab or a biosimilar will be administered intravenously per standard of care.
DRUG	Obinutuzumab	Obinutuzumab will be administered intravenously on days 1, 8, 15 of cycle 1 and then day 1 of cycles 2 to 12.

Timeline

• Start date: 2025-09-12
• Primary completion: 2032-01-01
• Completion: 2033-01-01
• First posted: 2025-02-13
• Last updated: 2026-04-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study